Introduction
Hyperglycemia, defined arbitrarily as a blood glucose level greater than 99 mg/dl, is common in critically ill patients, and particularly in those receiving total parenteral nutrition (TPN). As the population ages and the prevalence of overweight/obesity increases, the incidence of hyperglycemia during hospitalization may be expected to rise. Hyperglycemia has been shown to be associated with increased morbidity and mortality in a variety of disease states, including critical illness [1] , stroke [2] , myocardial infarction [3] [4] [5] and trauma [4] . It is likely that host risk factors (obesity, age, family history) and neurohormonal changes associated with illness are responsible for hyperglycemia by inducing peripheral insulin resistance and impairing pancreatic b-cell function. TPN may further worsen hyperglycemia because of the loss of the normal incretin response to oral feeding.
Relationship between glycemic control and outcomes
Because of the association between hyperglycemia and adverse outcomes, four large, prospective studies have been performed to determine whether lowering the average blood sugar with intensive insulin therapy (IIT) is associated with improved morbidity and mortality in critically ill patients (Table 1) [6,7,8 ,9 ] .
The first of these studies conducted by van den Berghe et al. [6] (Leuven 1) compared outcomes in a cohort of predominantly cardiothoracic ICU patients. The goal in the IIT group was to achieve blood sugars of 80-110 mg/ dl compared with standard of care (blood glucose 180-200 mg/dl). The IIT group had lower average blood sugars (103 AE 19 vs. 153 AE 33 mg/dl) and a higher rate of hypoglycemia (7 vs. 1%). The IIT group had an approximately 45% relative risk reduction in mortality Purpose of review In critically ill patients, nutrition support may be a life-saving intervention, but is not without risk. Adverse metabolic changes, including hypertriglyceridemia and hyperglycemia, are common. Hyperglycemia is associated with adverse outcomes, in particular, infection. Four major studies have addressed whether near-normal glycemia (80-110 mg/dl) in this clinical setting improves outcomes compared with blood sugars of approximately 150 mg/dl. The purpose of this review is to determine whether tight glycemic control is superior to moderate glycemic control (150 mg/dl) in critically ill patients receiving nutrition support. Recent findings Initial data collected in postsurgical patients suggested that near-normal glycemia dramatically improved outcomes compared with moderate glycemic control. However, three recent studies were unable to duplicate these results and suggest that the benefits of tight glycemic control may be limited to postsurgical patients. Controlling hyperlipidemia and preventing overfeeding may improve outcomes more than tight control of blood sugars. Furthermore, near-normal glycemic control caused frequent hypoglycemia and, in some cases, worsened outcomes. Summary Glycemic control to approximately 150 mg/dl is not inferior to near-normal glycemia in critically ill patients requiring nutrition support and is clearly safer. Lipid changes caused by insulin infusion may improve outcomes more than glycemic control itself, and prevention of hypertriglyceridemia should be a major focus of clinical care. (8 vs. 4.6%) and a 46% lower relative risk of blood stream infection, suggesting that treating hyperglycemia improves mortality by reducing infections rate. Subsequently, similar mortality benefits were reported by two other groups in both medical ICU (MICU) and surgical ICU (SICU) patients [10, 11] . Unfortunately, both these latter studies were observational and used historical control groups for comparison, limiting their validity. A follow-up study by Van den Berghe et al. [7] (Leuven 2) evaluated benefits of IIT in medical ICU patients. In this study, despite lower average blood sugars with IIT (100 vs. 155 mg/dl), no mortality benefit was seen. However, benefit was seen for IIT in the surrogate outcomes of ICU length of stay and new onset of renal failure. Brunkhorst et al. [8 ] prospectively evaluated the effect of IIT to achieve normoglycemia (blood glucose 80-110 mg/dl) in more than 500 septic patients. Mean blood sugars were again lower in the IIT group than in the control group (112 vs. 151 mg/dl); however, there was no apparent mortality benefit and hypoglycemia was four times more common in the IIT group (17 vs. 4%). The recently completed Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation trial (NICE-SUGAR) study evaluated the benefits of IIT in achieving near-normal glycemia in 6100 patients who were admitted to medical or surgical ICUs [9 ]. Groups were randomized to either blood glucose of less than 180 mg/dl (control group) or 81-108 mg/dl (IIT group). Blood sugar was lower in the IIT than in the control group (115 AE 18 vs. 145 AE 26 mg/dl), and hypoglycemia was more common in IIT than in control (6.8 vs. 0.5%). Surprisingly, the odds ratio for death in the IIT group was 1.14 (P ¼ 0.02), and IIT conferred a 2.5% absolute increase in mortality.
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Why the differences in outcomes?
The subject of why these four similar studies produced conflicting results has been perplexing. The initial Leuven study was conducted in surgical ICU patients, whereas the other three studies were performed in medical and surgical ICU settings. This suggests that perhaps postsurgical patients benefit more from achieving normoglycemia. NICE-SUGAR study and Brunkhorst et al. [8 ] found no differences in outcomes on the basis of recent surgical procedure, indicating that recent surgical history is not solely responsible for the differences in outcomes between the studies. Studies conducted almost 20 years ago showed that routine use of TPN in malnourished postsurgical patients increased infection rates, possibly related to TPN-induced hyperglycemia [12] . It should be noted, however, that the standards of care for catheter site hygiene have dramatically improved since the publication of this early study, so that the overall impact of hyperglycemia on catheter-associated sepsis may have been overestimated. Therefore, studies in which most patients are postsurgical and receive at least some parenteral nutrition (Leuven 1) are more likely to show benefit from tighter glycemic control than studies conducted in a mixed MICU/SICU setting in which at least 50% of patients were receiving enteral nutrition (NICE-SUGAR, Brunkhorst et al. [8 ] , Leuven 2).
A key difference between these four studies is the implementation and method of providing nutrition support. Analyzing the studies with respect to caloric delivery requires some assumptions, given missing data in all studies. In studies in which protein intake is not clearly stated, I have assumed 1 g/kg/day. As body weight is not given in either of the Leuven studies, assuming an average height of 1.75 m for men and 1.62 m for women in each study, average body weight is approximately 72 kg. Overfeeding with nutrition support clearly increases morbidity and mortality [12, 13] , possibly due, in part, to hyperglycemia. As most patients in these studies were overweight or obese, their resting energy expenditure was likely lower per kilogram of body weight than that of a patient of normal body weight due to a greater proportion of body weight being composed of relatively metabolically inactive adipose tissue. Accumulating data also suggest that critical illness and recent surgery do not markedly increase energy expenditure above that predicted by the Harris-Benedict equation [14, 15] . On the basis of the BMI of the patients in each study, it is likely that the patients in both Leuven studies were actually overfed, increasing the likelihood of developing not only hyperglycemia but also metabolic acidosis, hypertriglyceridemia and fatty liver. As noted, overfeeding in postoperative patients is particularly problematic, increasing the rates of infection [12] . It is, therefore, not surprising that a predominantly postsurgical group benefited from limitation of hyperglycemia when being Near-normal glycemia in critical illness Reeds 153 Table 1 The average blood sugar with intensive insulin therapy is associated with improved morbidity and mortality in critically ill patients Leuven 1 [6] Leuven 2 [7] Brunkhorst et al. [ overfed, as suggested by Leuven 1. Indeed, it is possible that the benefits of hypocaloric feeding [16] masked any benefit of glycemic control in the NICE-SUGAR study and study by Brunkhorst et al. [8 ] . It is likely that the benefit of IIT may have disappeared had the patients in Leuven 1 not been overfed.
A final point to consider is that of the metabolic effects of insulin beyond glycemic control. Early studies dating to the 1960s [17] , and more recent meta-analyses [18] , indicate that an infusion of glucose, insulin and potassium improves outcomes in patients with acute coronary syndromes, suggesting that it is not hyperglycemia per se that worsens outcomes, but possibly that hyperinsulinemia confers metabolic and clinical benefit. Insulin has a number of potentially helpful actions in critical illness; it suppresses lipolytic rate, sequesters fatty acids into intracellular lipid stores, lowers plasma and possibly intracellular free fatty acid concentration that may reduce tissue 'lipotoxicity', and by limiting fatty acid availability, increases myocardial glucose utilization. These changes may improve left ventricular function and cardiac efficiency. Insulin may also attenuate the increase in wholebody proteolytic rate that occurs in critical illness, ameliorating loss of lean body mass, which is tightly related to outcome. Insulin also rapidly reduces plasma triglyceride concentration. Post-hoc analysis of data from more than 350 patients who had ICU stays over 7 days in Leuven 1 showed that plasma triglyceride rose approximately 80% from baseline in the control group compared with no change with IIT [19] . There was an almost linear relationship between triglyceride concentration and mortality. Indeed, patients with triglyceride of less than 100 mg/dl had a mortality rate of only 5% compared with a 40% mortality rate in patients with triglyceride of more than 300 mg/dl. Although hyperglycemia increases plasma triglyceride, overfeeding and TPN are both well known to increase the risk of hypertriglyceridemia. Taken together, these results suggest that overfeeding in Leuven I contributed to metabolic disturbances that could be attenuated by insulin infusion. Therefore, although benefit was seen, this was due to metabolic actions of insulin other than glycemic control.
Is near-normal glycemia dangerous?
Although focus has been placed on hyperglycemia, the relationship between mean blood glucose level and outcomes is a J-shaped curve in which both hyperglycemia and hypoglycemia are associated with poorer outcomes [20] . Bagshaw et al. [20] evaluated the relationship between average blood sugar and outcomes in a cohort of 66 000 patients admitted to the ICU and found that blood sugars in both the highest (adjusted odds ratio 1.10) and lowest (adjusted odds ratio 1.29) range were associated with worse outcomes. These findings have been validated by both NICE-SUGAR and Brunkhorst et al.'s [8 ] studies, indicating that the risk of hypoglycemia is dramatically greater with IIT and suggesting that this could contribute to the poorer outcomes with IIT seen in the NICE-SUGAR study.
Conclusion
From these studies, some conclusions can be drawn. Overfeeding, and probably hyperglycemia, increase risk of infection in surgical patients. Near-normal glycemia improves outcomes in this setting; however, limiting nutrition support to appropriate patients and prevention of overfeeding are likely to be equally effective and safer. If patients are not overfed, then it is likely that there is no dramatic benefit from achieving normoglycemia with IIT in critical illness compared with blood glucose of less than 150-180 mg/dl. There is clear evidence of risk with IIT, and in the absence of clear data showing benefit, particularly in MICU patients, maintaining blood glucose less than 180 mg/dl but not less than approximately 100 mg/dl is likely to result in better outcomes. Insulin action on lipid and protein metabolism could explain the beneficial effects of early IIT and should be evaluated with larger prospective studies.
